CGRP as a new target in prevention and treatment of migraine

摘要

Calcitonin-gene-related peptide (CGRP), which is released during migraine attacks, has been identified as a possible target for the treatment of migraine.1 CGRP is located in sensory nerve endings in cranial bloodvessels and is a potent dilator of cerebral arteries.2 Its receptors are also found in many brain areas, including the central trigeminal system.3 Therefore, CGRP antagonists were developed for the treatment of acute migraine attacks (panel), and they were suggested as a possible treatment for patients with contraindications for triptans, such as those with angina or after myocardial infarction or stroke. However, CGRP antagonists are no longer being developed for the treatment of acute migraine attacks, probably because of the hepatic signal aftertheir long-term use.